Vice President for Chemistry
Peter Senter joined Seattle Genetics in August 1998 and now serves as Vice President of Chemistry. His group carries out research in anticancer drug design, antibody-drug conjugate technologies for cancer therapy, and protein glycoengineering. Several of the molecules generated in Dr. Senter’s lab have entered clinical trials, and two of them have been approved: Adcetris for relapsed Hodgkin lymphoma and certain non-Hodgkin lymphoma, and Etopophos for solid tumor therapy. Dr. Senter has authored more than 150 scientific publications and holds more than 40 issued patents. He received an AB in Biochemistry from the University of California, Berkeley, a PhD in Chemistry from the University of Illinois, and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Göttingen, Germany. He is the Senior Editor of Molecular Cancer Therapeutics, on the Editorial Advisory Boards of several other journals, and serves as an Affiliate Professors at the University of Washington Department of Bioengineering and the University of Southern California School of Pharmacy.